every AI newsletter, huaxi biology (SH 688363, closing price: 61.75 yuan) announced on the evening of March 5 that as of February 29, 2024, huaxi biotechnology co., ltd. had bought back about 2.71 million shares of the company through centralized bidding through the trading system of Shanghai stock exchange, accounting for 0.5626 of the company's total share capital of about 0.482 billion shares, the highest price of the repurchase transaction is 89.71 yuan/share, the lowest price is 56.9 yuan/share, and the total amount of funds paid is about 0.183 billion yuan.

from January to December 2022, huaxi biology's operating income will be composed of biotechnology accounting for 99.99 percent.

The chairman and general manager of Huaxi Biology are Zhao Yan, female, 58 years old, with a master's degree.

as of press release, Huaxi biological market value is 29.7 billion yuan.

Dow (daoda1997) "individual stock trend" reminder:

1. Huaxi Bio's northbound capital holdings increased by 1.3611 million shares in the past 30 days, accounting for 0.69 of the outstanding shares;

2. No organization has conducted research on Huaxi Biology in the past 30 days.

every headline (nbdtoutiao)- every interview with Zhou hanmin, member of the standing Committee of the national Committee of the chinese people's political consultative conference and former vice chairman of the central Committee of the people's democratic construction: it is suggested to formulate "guidelines for certification of important data" and "negative list for exemption from declaration of data exit"

(Reporter Wang Hanli)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Operate accordingly at your own risk.